Shire receives CHMP positive opinion for ADHD drug Intuniv
24 July 2015 | By Victoria White
The CHMP has adopted a positive opinion recommending the approval of Shire’s Intuniv for the treatment of ADHD in children and adolescents...
List view / Grid view
News
Aromatase inhibitors substantially reduce breast cancer deaths
24 July 2015 | By Victoria White
A study of more than 30,000 women shows that aromatase inhibitors substantially reduce the risk of death in postmenopausal women ER-positive breast cancer...
Type 2 diabetes mellitus treatment market value will reach $39b by 2021
23 July 2015 | By Victoria White
The global market for type 2 diabetes mellitus therapeutics will rise in value from $23.5 billion in 2014 to an estimated $39 billion by 2021, driven primarily by rising disease prevalence and the continued uptake of recently approved and emerging branded treatments, according to business intelligence provider GBI Research.
Amgen submits sNDA for Kyprolis in relapsed multiple myeloma
23 July 2015 | By Victoria White
Amgen has submitted a sNDA to the US FDA for Kyprolis to seek an expanded indication for the treatment of patients with relapsed multiple myeloma...
EMA validates two Opdivo indication extension applications
23 July 2015 | By Victoria White
The EMA has validated two type II variation applications which seek to extend the indication of Opdivo in non-squamous NSCLC and advanced melanoma...
EC approves Keytruda for the treatment of melanoma
23 July 2015 | By Victoria White
The EC has approved Merck’s Keytruda (pembrolizumab) for the treatment of advanced (unresectable or metastatic) melanoma in adults...
Florbetapir scans help with patient diagnosis and management
23 July 2015 | By Victoria White
New data shows that knowledge of amyloid status as determined by Florbetapir F 18 Injection imaging altered diagnosis and management of patients...
Depomed receives unsolicited proposal from Horizon Pharma
23 July 2015 | By Victoria White
Depomed has confirmed that it has received an unsolicited proposal from Horizon Pharma to acquire all of the outstanding shares of Depomed...
J&J and Norvatis to fight it out in the axSpA treatment space
22 July 2015 | By Victoria White
Stelara has progressed into Phase III development for axSpA and, following its anticipated approval, is forecast to achieve sales of $244.7 million in 2024...
Comark Instruments prevents high-volume, high-value inventory spoilage and significant revenue loss for VH Bio
22 July 2015 | By Comark Instruments
VH Bio is a leading supplier and distributer for the Life Sciences industry within the United Kingdom and Republic of Ireland...
Promising Phase 3 results for E/C/F/TAF regimen presented at IAS
22 July 2015 | By Victoria White
Detailed 48-week data from a Phase 3 study evaluating E/C/F/TAF regimen in patients with HIV-1 was presented at the 8th IAS Conference...
Aducanumab demonstrates promising Phase 1b results in Alzheimer’s disease
22 July 2015 | By Victoria White
Biogen has announced new results from an interim analysis of the Phase 1b PRIME study of aducanumab in patients with prodromal or mild Alzheimer’s disease...
Data suggests Lilly’s solanezumab slows progression of mild Alzheimer’s
22 July 2015 | By Victoria White
Lilly has announced results suggesting that solanezumab slows the progression of Alzheimer's in patients with mild disease...
Novavax announces positive top-line data from Phase 1 Ebola vaccine trial
22 July 2015 | By Victoria White
Novavax has announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein recombinant nanoparticle vaccine candidate...
Phase III study of selumetinib in uveal melanoma fails to meet primary endpoint
22 July 2015 | By Victoria White
A Phase III study of selumetinib in combination with dacarbazine for the treatment of metastatic uveal melanoma failed to meet its primary endpoint...
